Early clinical experience with subcutaneous GR43175 in acute migraine: an overview
Research output: Contribution to journal › Journal article › Research › peer-review
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.
|Journal||Cephalalgia : an international journal of headache|
|Volume||9 Suppl 9|
|Number of pages||5|
|Publication status||Published - 1989|
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Indoles, Injections, Subcutaneous, Male, Middle Aged, Migraine Disorders, Sulfonamides, Sumatriptan